2月14日，天益医疗宣布完成对老牌血透龙头日机装CRRT（连续性肾脏替代治疗）业务的收购。当天，天益医疗再公告称，拟通过新加坡全资子公司潽莱马克隆向BELLCO S.R.L.收购其CRRT-滤器业务资产。

公开资料显示，BELLCO在CRRT领域拥有深厚的技术积累和丰富的行业经验。其CRRT-滤器产品在欧洲乃至全球市场拥有一定的客户基础和良好口碑。

Together with Bellco Glass, Cytomatrix is offering 10.5 mm diameter Cellfoam disks for use in 48-well culture plates. Bone marrow cells on Cellfoam The idea for Cellfoam, however, originated with ...

为实现此次收购，bellco s.r.l.计划将其crrt-滤器业务资产剥离至其新设立的一家全资子公司，随后天益医疗的新加坡子公司潽莱马克隆将通过收购这家 ...

Symbiotic Capital - which starts life with more than $600 million at its disposal - is an affiliate of Bellco Capital, an investment form set up by Arie Belldegrun, a biotech entrepreneur formerly ...